Agilis Biotherapeutics, LLC, a NYC-based synthetic biology-based company focused on rare genetic diseases, completed an $8m financing.
The company intends to use the funds to develop a treatment for Friedreich’s ataxia (FRDA) in collaboration with Intrexon Corporation (NYSE: XON), a leader in the field of synthetic biology.
Agilis and Intrexon recently executed an Exclusive Channel Collaboration (ECC) through which Agilis intends to develop and commercialize novel DNA-based therapeutics for the treatment of FRDA. Under the collaboration, the company also has an option to expand its relationship with Intrexon by adding another rare genetic disease to the collaboration.
Friedreich’s ataxia is a rare genetic neurodegenerative disease that results in a physically debilitating, life shortening condition.